Our in vivo studies showed for the first time the benefit of simultaneous treatment of doxorubicin with a TGFβ antagonist to improve the inhibition of tumor growth and lung/bone metastasis in a syngeneic immunocompetent murine xenograft model and in a nude mice xenograft model of human breast cancer. Here, TGFB1 is linked to breast carcinoma.